Liver toxicity during temozolomide chemotherapy caused by Chinese herbs

BMC Complementary and Alternative Medicine

Alexander Egle²  Richard Greil²  Martin Moik²  Clemens Hufnagl²  Michael Strasser¹  Michael Grundbichler²  Lukas Weiss²  Teresa Magnes²  Thomas Melchardt² 

[1] Department of Internal Medicine I, Paracelsus Medical University Salzburg, Austria, Müllner-Hauptstrasse 48, Salzburg 5020, Austria;Department of Internal Medicine III, Salzburg Cancer Research Institute, Paracelsus Medical University Salzburg, Austria, Müllner-Hauptstrasse 48, Salzburg 5020, Austria

关键词: Hepatitis;    Liver toxicity;    Interaction;    Chinese herbs;    Temozolomide;   

Others  :  1220208
DOI  :  10.1186/1472-6882-14-115

 received in 2014-01-03, accepted in 2014-03-27,  发布年份 2014

【 摘 要 】

Background

Complementary and alternative medicine is often used by patients with malignant glioma. Although several interactions of various alternative agents with chemotherapy are known, none has been described for temozolomide so far.

Case presentation

We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma. After cessation of the herbal formula as well as the chemotherapy liver enzymes slowly normalized. Due to tumor progression the patient was retreated with temozolomide for 5 cycles without toxicity. Because of further progression combination treatment of bevacizumab and irinotecan was started and again no liver toxicity was observed.

Conclusions

We conclude that the observed toxicity with jaundice was probably caused by an interaction of this popular Chinese formula and temozolomide. This is the first report about a relevant interaction of temozolomide and any herbal formula.

【 授权许可】

   
2014 Melchardt et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Heese O, Schmidt M, Nickel S, Berger H, Goldbrunner R, Tonn JC, Bahr O, Steinbach JP, Simon M, Schramm J, Krex D, Schackert G, Reithmeier T, Nikkhah G, Löffler M, Weller M, Westphal M, German Glioma Network: Complementary therapy use in patients with glioma: an observational study. Neurology 2010, 75:2229-2235.
• [2]Sarganas G, Orzechowski HD, Klimpel A, Thomae M, Kauffmann W, Herbst H, Bronder E, Garbe E: Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. Neuro Oncol 2012, 14:541-546.
• [3]Pao LH, Hu OY, Fan HY, Lin CC, Liu LC, Huang PW: Herb-drug interaction of 50 Chinese herbal medicines on CYP3A4 activity in vitro and in vivo. Am J Chin Med 2012, 40:57-73.
• [4]Ong ES, Len SM, Lee AC, Chui P, Chooi KF: Proteomic analysis of mouse liver for the evaluation of effects of Scutellariae radix by liquid chromatography with tandem mass spectrometry. Rapid Commun Mass Spectrom 2004, 18:2522-2530.
• [5]Du J, Xing Q, Xu L, Xu M, Shu A, Shi Y, Yu L, Zhang A, Wang L, Wang H, Li X, Feng G, He L: Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics 2006, 7:831-841.
• [6]Chang L, Su J, Jia X, Ren H: Treating malignant glioma in Chinese patients: update on temozolomide. Onco Targets Ther 2014, 7:235-244.
• [7]Meijerman I, Beijnen JH, Schellens JH: Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 2006, 11:742-752.
• [8]Golden EB, Lam PY, Kardosh A, Gaffney KJ, Cadenas E, Louie SG, Petasis NA, Chen TC, Schonthal AH: Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009, 113:5927-5937.
• [9]Perrone G, Hideshima T, Ikeda H, Okawa Y, Calabrese E, Gorgun G, Santo L, Cirstea D, Raje N, Chauhan D, Baccarani M, Cavo M, Anderson KC: Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 2009, 23:1679-1686.